Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, placebo-controlled, double-blind Phase 1 study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of R835 in healthy subjects

Trial Profile

A randomized, placebo-controlled, double-blind Phase 1 study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of R835 in healthy subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 Jun 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs R 835 Rigel Pharmaceuticals (Primary) ; Lipopolysaccharide
  • Indications Autoimmune disorders
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics

Most Recent Events

  • 06 Jun 2020 Results presented at the 21st Annual Congress of the European League Against Rheumatism
  • 03 Jun 2020 According to a Rigel Pharmaceuticals media release, data from this study will be presented at the European League Against Rheumatism (EULAR) 2020 E-Congress taking place June 3-6, 2020.
  • 03 Jun 2020 Results published in the Rigel Pharmaceuticals media release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top